Stock AVBP ARRIVENT BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus ArriVent BioPharma, Inc.

Equities

AVBP

US04272N1028

Market Closed - Nasdaq
Other stock markets
 15:59:51 2024-05-29 EDT 		5-day change 1st Jan Change
18.96 USD -0.05% Intraday chart for ArriVent BioPharma, Inc. -4.96% 0.00%
05-16 ArriVent BioPharma, Inc. Appoints John Hohneker as Board of Directors CI
05-08 ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on ArriVent BioPharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

74b2ac90b20ad8f29bc206c1.9-xof18AnOmitA2cVwIp8iBZZeddW5pVmvhe7Tl2GqA.xYgKCjdW3bGR8jvIMnJYhFV0EIE-AtcC854ctFw4SviHlCEOFm_vtpXVSA~31b05ba4137dccea7ff7fecf42d7fa02

Analyst Recommendations on ArriVent BioPharma, Inc.

HC Wainwright Initiates ArriVent BioPharma With Buy Rating, $25 Price Target MT
LifeSci Capital Starts ArriVent BioPharma With Outperform Rating, $33 Price Target MT
Citigroup Starts ArriVent BioPharma With Buy Rating, $30 Price Target MT
Jefferies Starts ArriVent BioPharma With Buy Rating, $35 Price Target MT
Goldman Sachs Initiates ArriVent BioPharma With Buy Rating, Price Target is $27 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.78 USD
Average target price
30.2 USD
Spread / Average Target
+60.81%
High Price Target
35 USD
Spread / Highest target
+86.37%
Low Price Target
25 USD
Spread / Lowest Target
+33.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ArriVent BioPharma, Inc.

HC Wainwright
Jefferies & Co.
Citigroup
LifeSci Capital
Goldman Sachs

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. AVBP Stock
  4. Consensus ArriVent BioPharma, Inc.